Characteristics associated with suppression of spermatogenesis in a male hormonal contraceptive trial using testosterone and Nestorone<sup>®</sup>gels
Mara Y. Roth(University of Washington), John K. Amory(University of Washington), Diana Blithe(National Institutes of Health), Régine Sitruk‐Ware(Population Council), Clint Dart(Health Decisions (United States)), Ronald S. Swerdloff(University of California, Los Angeles), Narender Kumar(Population Council), Stephanie T. Page(University of Washington), Noa Chapal Ilani(The Lundquist Institute), William J. Bremner(University of Washington Medical Center), Changfeng Wang(The Lundquist Institute)
Cited by 31
Related Papers
Age Trends in the Level of Serum Testosterone and Other Hormones in Middle-Aged Men: Longitudinal Results from the Massachusetts Male Aging Study
|The Journal of Clinical Endocrinology & Metabolism|2002|1.8k
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline
|The Journal of Clinical Endocrinology & Metabolism|2018|1.6k
Advances in Male Contraception
|Endocrine Reviews|2008|1.1k
Effects of Testosterone Treatment in Older Men
|New England Journal of Medicine|2016|864
Long-Term Testosterone Gel (AndroGel) Treatment Maintains Beneficial Effects on Sexual Function and Mood, Lean and Fat Mass, and Bone Mineral Density in Hypogonadal Men
|The Journal of Clinical Endocrinology & Metabolism|2004|652